Dimethyl Fumarate, another FDA-approved drug with a mixed mechanism of action that includes an anti-inflammatory activity, was reported effective in ameliorating PD features in an alpha-synuclein based model of PD (Lastres-Becker et al., 2016). Here, SNCA is linked to Parkinson disease.